Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Discovery Laboratories Inc (DSCO)

DSCO RSS Feed
Add DSCO Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 8/20/2014 3:25:47 PM - Followers: 102 - Board type: Free - Posts Today: 0

The Big Day is Coming!!!!!!!!!!


 The FDA classified the review of the Complete Response as a Class 2 review and established March 6, 2012 as the target action date under the Prescription Drug User Fee Act (PDUFA) to complete its review and potentially grant marketing approval for SURFAXIN.

 





Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant therapies to treat respiratory disorders and diseases based on its KL4 surfactant and capillary aerosol-generating technologies. Its development stage products include Surfaxin, a synthetic, peptide-containing surfactant in phase III clinical trial for the prevention of respiratory distress syndrome in premature infants; Surfaxin LS, a Phase III trial product to improve ease of use for healthcare practitioners; and Aerosurf, an aerosolized KL4 surfactant that has completed first pilot Phase II clinical trial for the treatment of respiratory distress syndrome in premature infants.

The company has a license agreement with Philip Morris USA Inc. to use its capillary aerosolization technology for use with pulmonary surfactants for the respiratory diseases and conditions; and a strategic alliance agreement with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain.

Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.



 

MUST READ!!!!!!!!!!!!!!!!!

  On May 11, 2011, the Company issued a press release highlighting the results of operations for the quarter ended March 31, 2011, and providing an update on its pipeline development as follows:
 
Surfaxin® (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants: The Company is conducting a comprehensive preclinical program to validate its optimized biological activity test (BAT), a key remaining issue that must be addressed to potentially gain U.S. Food and Drug Administration (FDA) marketing approval for Surfaxin in the United States.  The Company has had several interactions with the FDA intended to ensure that the comprehensive preclinical program would ultimately satisfy the FDA.  In January 2011, the Company announced that the FDA had provided guidance to increase the sample size of a specific data set by testing additional Surfaxin batches.  To comply with the FDA's suggestion, the Company has successfully manufactured eight Surfaxin batches and presently plans to manufacture two additional Surfaxin batches for use in the comprehensive preclinical program. The Company presently plans to complete all related analytical testing and concordance studies, and be in a position to file a Surfaxin Complete Response in the third quarter of 2011.
 
Surfaxin LSTM (lyophilized lucinactant) for neonatal RDS :  The Company continues to advance this program. Its plans for 2011 include establishing a commercial-scale manufacturing capability at a cGMP-compliant contract manufacturer with expertise in lyophilized formulations and seeking regulatory guidance from the FDA and the European Medicines Agency (EMA) for the planned clinical development program.
 
Aerosolization Technology :  Recently, at the 2011 Pediatric Academic Societies Annual Meeting (PAS), new data was presented including: (i) a collaborative study indicating that aerosolized KL4 surfactant significantly improved lung function and survival when treating Acute Lung Injury in a well established preclinical model of this severe respiratory condition, (ii) a dose-ranging assessment of aerosolized KL4 surfactant in a widely recognized preclinical model of RDS, demonstrating significant improvement in lung function, lung structural integrity and pulmonary inflammatory mediator profile following treatment with aerosolized KL4 surfactant versus controls, and (iii) a study highlighting the Company's novel patient interface technology intended to increase the efficiency of pulmonary aerosol drug delivery to patients requiring positive pressure ventilatory support.
 
 
2

 

 
 
Regarding the Company's lead aerosolized KL4 surfactant program, Aerosurf® (aerosolized lucinactant for neonatal RDS), data from the preclinical dose ranging assessment study presented at PAS mentioned above suggests that, out of several doses tested, KL4 surfactant delivered via the Company's proprietary capillary aerosol generator during a 20 to 30 minute dosing interval results in the most favorable physiologic outcomes.  This study provides guidance for future clinical dosing strategies for this program. The Company's plans for 2011 include finalizing the clinical and potential commercial design of the capillary aerosol generator, finalizing the clinical and potential commercial design for the novel patient interface, and seeking regulatory guidance in the U.S. and Europe for the planned development program.
 
For the quarter ending June 30, 2011, the Company projects cash outflow of $5.8 million.

 





 

Investor Relations Contacts

John G. Cooper
Executive Vice President, Chief Financial Officer
Discovery Laboratories, Inc.
2600 Kelly Road, Suite 100
Warrington, PA 18976
Tel. 215.488.9490
Fax. 215.488.9391
jcooper@discoverylabs.com


 



As of November 8, 2011, 24,499,497 shares of the registrant's common stock, par value $0.001 per share, were outstanding

As of  May 2, 2011, 24,178,502 shares of the registrant's common stock, par value $0.001 per share, were outstanding.  AutAeeeeee

Authorized 50 Mill

85 BM's 5-15-11



 

 

 

2010-11 Press Releases

 

May 13, 2011 10-Q http://ih.advfn.com/p.php?pid=nmona&article=47677338 

May 13, 2011 http://ih.advfn.com/p.php?pid=nmona&article=47666790       A Brighter Decade Ahead for Biotech - Equity Research on Discovery Laboratories and Mylan Inc   

May 11, 2011 8k http://ih.advfn.com/p.php?pid=nmona&article=47626029     

May 19, 2010
Discovery Labs Achieves Key Milestone Towards Potential Surfaxin® Approval

May 17, 2010
Discovery Labs' KL4 Surfactant Demonstrates Potential Protective Role for Lung Transplantation in Established Preclinical Model

May 14, 2010
Discovery Labs' Phase 2a Aerosurf® Study Published in Journal of Aerosol Medicine and Pulmonary Drug Delivery

May 5, 2010
Surfaxin LSTM Improves Pulmonary Function and Reduces Lung Inflammation in Established Model of Respiratory Distress Syndrome

April 28, 2010
Discovery Labs' KL4 Surfactant Data to be Presented at Pediatric Academic Societies Annual Meeting and American Thoracic Society International Conference

April 27, 2010
Discovery Labs Provides Updates on Surfaxin®, Other Key Programs and First Quarter 2010 Financial Results

March 10, 2010
Discovery Labs Reports Fourth Quarter 2009 Financial Results and Provides Business Update

February 23, 2010
Discovery Labs Announces Completion of $16.5 Million Public Offering

February 18, 2010
Discovery Labs Prices $16.5 Million Public Offering of Common Stock and Warrants

February 17, 2010
Discovery Labs Announces Proposed Public Offering of Common Stock and Warrants

February 16, 2010
Discovery Labs Receives FDA Guidance Regarding Pathway to Potential SURFAXIN® Approval

January 19, 2010
POPG, a Key Component of Discovery Labs KL4 Surfactant, Identified as a Novel Anti-Viral Therapeutic Approach

 



Management Team View Bio

W. Thomas Amick, Interim CEO

Russell Clayton, D.O.
Vice President, Academic and Medical Affairs, Acting Head, Regulatory Affairs and Preclinical Research

Kathryn Cole
Senior Vice President, Human Resources

John G. Cooper
Executive Vice President, Chief Financial Officer

David L. Lopez, C.P.A., Esq.
Executive Vice President, General Counsel

Charles F. Katzer
Senior Vice President, Manufacturing Operations

Thomas F. Miller, Ph.D., MBA
Senior Vice President, Commercialization & Corporate Development

Gerald J. Orehostky
Senior Vice President, Quality Operations

Robert Segal, M.D., F.A.C.P.
Senior Vice President, Medical & Scientific Affairs, Chief Medical Officer

Mary B. Templeton, Esq.
Senior Vice President, Deputy General Counsel

 



Do your own DD & trade smart

(DSCO) Pre-Market Trading     (DSCO) After Hours Trading

(DSCO) Short

Technical Indicators (Barchart) 

Yahoo! Finance (i.e Real-Time)

Last update: June 03,2010

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
DSCO
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for DSCO
DSCO News: Small Company Offering and Sale of Securities Without Registration (d) 10/21/2014 04:19:07 PM
DSCO News: Current Report Filing (8-k) 10/15/2014 07:49:39 AM
DSCO News: Discovery Labs Announces Strategic Collaboration With Battelle For AEROSURF® Program 10/15/2014 07:30:00 AM
DSCO News: Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address ... 10/01/2014 08:00:00 AM
DSCO News: Quarterly Report (10-q) 08/07/2014 05:26:41 PM
PostSubject
#2723   was just about to get in. nice move dshade 08/20/14 03:25:47 PM
#2722   Discovery Laboratories Research Coverage Started at Stifel Nicolaus sch100 08/20/14 06:02:35 AM
#2721   Thank you for posting that. someconcerns 08/06/14 01:29:04 PM
#2720   $DSCO Roth Capital Maintains Buy On Discovery maytepper 08/06/14 12:48:35 PM
#2719   It looks like someone knows something. Went big bambino 07/07/14 02:22:17 PM
#2718   yes, it's significant funding and a vote of king oil 06/18/14 04:54:31 PM
#2717   Saw that; a very big deal. Now someconcerns 06/18/14 03:22:41 PM
#2716   Discovery Laboratories Climbs Pre-Market on Receipt of $1.9 king oil 06/17/14 09:30:02 AM
#2715   New article by Larry Smith, FWIW: someconcerns 06/11/14 09:50:41 AM
#2714   A POS rises: PVCT Robbay 06/06/14 11:43:58 PM
#2713   Rob, Give us the proposed text of your two someconcerns 06/05/14 08:40:26 PM
#2712   How do we go about doing so? How dmwes4 06/05/14 02:20:38 PM
#2711   Nathan Fischel and Fariba Ghodsian: Robbay 06/05/14 07:56:44 AM
#2710   John G. Cooper you need to retire: Robbay 06/03/14 01:29:06 PM
#2709   Dsco is a sales target: Robbay 06/02/14 10:10:35 AM
#2708   Jefferson Research drops coverage for DISCOVERY LABORATORIES INC. king oil 05/30/14 11:23:54 AM
#2707   Agree overpaid executives, responsible for a number of BioChica 04/22/14 08:11:55 PM
#2706   Phase II: The drug or treatment is given BioChica 04/22/14 07:53:40 PM
#2705   High open interest on calls for May and FatCat_Banker 04/08/14 10:57:42 PM
#2704   Interesting, do you see the summer as a lifting point? Robbay 04/04/14 03:24:22 PM
#2703   I totally understand. FatCat_Banker 04/04/14 12:46:50 AM
#2702   Fat Cat: Robbay 03/30/14 08:58:48 PM
#2701   It's ok, man. We have until the 3Q. FatCat_Banker 03/29/14 02:53:50 PM
#2700   Carl Icahn we need Your HELP! Robbay 03/25/14 12:40:48 PM
#2699   I agree with you someconcerns, Robbay 03/04/14 02:44:18 PM
#2698   Robbay, I'm long term as well, with the first someconcerns 03/04/14 12:42:22 PM
#2697   Someconcers: I have been a long time holder of Robbay 03/04/14 11:50:04 AM
#2696   At least it would be a positive action, someconcerns 03/03/14 09:58:53 PM
#2695   Ya think? boogie42 03/03/14 08:02:10 PM
#2694   Why don't you consider calling them to express someconcerns 03/02/14 05:34:35 PM
#2693   Put lipstick on this: Robbay 03/02/14 02:52:30 PM
#2692   Just looking briefly at her I can say SmurfVA 02/23/14 09:42:58 PM
#2691   Good news is long overdue. someconcerns 02/18/14 10:48:13 AM
#2690   Our time maybe here. Higher then avg big bambino 02/18/14 10:11:18 AM
#2689   The S-3: someconcerns 02/06/14 09:04:55 PM
#2688   What was the nature of the S3 form someconcerns 01/24/14 01:43:35 PM
#2687   cc transcript ECole 11/15/13 02:58:26 AM
#2686   Discovery Labs Reports Third Quarter 2013 Financial Results starbuxsux 11/12/13 05:45:27 PM
#2685   I'm serious about the 15% return I clocked starbuxsux 11/12/13 04:56:55 PM
#2684   massive loss for years to come,,are u serious,,pos myop kingsransome 11/12/13 04:53:19 PM
#2683   Discovery Labs Receives FDA Clearance of IND to starbuxsux 11/12/13 04:36:34 PM
#2682   1.75 warrants,,,still there??? kingsransome 11/12/13 10:51:06 AM
#2681   they changed earnings release to after market,,not good sign,,myop. kingsransome 11/12/13 09:24:06 AM
#2680   Thank you Piper Jaffrey! sch100 11/12/13 07:56:23 AM
#2679   looking good!! starchaser 11/11/13 10:19:52 PM
#2678   Piper Jaffray $6 price target king oil 11/11/13 09:25:12 AM
#2677   upgraded $6 price target $$$$$$$$$,,sweet news myopppp kingsransome 11/11/13 08:05:02 AM
#2676   2.87 warrant$$$$$$$$$$$ sweet myop kingsransome 11/08/13 12:57:58 PM
#2675   8:07AM Discovery Labs announces U.S. commercial launch of surf1944 11/08/13 11:27:56 AM
#2674   so far looks like the market doesn't care. king oil 11/08/13 10:21:46 AM
PostSubject